Addiction Medicine
Conference Coverage
Long-acting naltrexone effective in alcohol use disorder
“ED patients are at higher risk of complications for AUD simply because they are in the ED in the first place – initiating AUD treatment in this...
Commentary
More on varenicline
Murray et al have written a timely, thoughtful, and useful article (“Smoking cessation: Varenicline and the risk of neuropsychiatric adverse...
For Residents
Postop analgesia in Saudi Arabia and the United States: A resident’s perspective
I had the opportunity to experience first-hand acute postoperative pain management in both the United States and Saudi Arabia.
From the Journals
Safer opioid supply program in Canada helps those who face overdose risks
“It’s a contentious issue, but it makes so much sense that, if what’s killing people is highly toxic drugs, we need to find a way to provide an...
Commentary
Could a vaccine (and more) fix the fentanyl crisis?
The first human trial is underway right now for a vaccine against oxycodone. Not only that, but there are other vaccines that are in animal trials...
From the Journals
Heart failure drug a new treatment option for alcoholism?
Researchers “have observed that patients with AUD often present with changes in peripheral hormones, including aldosterone, which plays a key role...
From the Journals
Minorities hit especially hard by overdose deaths during COVID
Expanding access to naloxone, fentanyl test strips, and treatments for substance use disorders to disproportionately affected populations is...
From the Journals
Urgent need for research into psychedelic therapy for older adults
Little is known about appropriate dosing, pharmacokinetics, and pharmacodynamics of psychedelics in older adults.
From the Journals
Clozapine may be best choice for cutting SUD risk in schizophrenia
Research on the effectiveness of pharmacotherapies for schizophrenia and comorbid substance use disorder is “very sparse.”
Feature
Largest-ever study into the effects of cannabis on the brain
“The study wants to bring the two sides of the argument together and understand what’s really happening.”
From the Journals
Psychiatrists’ views on psychoactive drugs clash with U.S. policy
Survey respondents viewed psilocybin and ketamine as similarly safe – and safer than methamphetamine and alprazolam.